

Hideo Wada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1926984/publications.pdf>

Version: 2024-02-01

240
papers

9,487
citations

61687

45
h-index

53065

89
g-index

249
all docs

249
docs citations

249
times ranked

6614
citing authors

#	ARTICLE	IF	CITATIONS
1	Platelet Activation and Thrombosis in COVID-19. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 055-061.	1.5	17
2	D-dimer kit with a High FDP/D-Dimer Ratio is Useful for Diagnosing Thrombotic Diseases. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962110705.	0.7	7
3	Proposal of Quick Diagnostic Criteria for Disseminated Intravascular Coagulation. <i>Journal of Clinical Medicine</i> , 2022, 11, 1028.	1.0	4
4	Elevated Plasma Soluble C-Type Lectin-like Receptor 2 Is Associated with the Worsening of Coronavirus Disease 2019. <i>Journal of Clinical Medicine</i> , 2022, 11, 985.	1.0	14
5	Characteristics Behaviors of Coagulation and Fibrinolysis Markers in Acquired Thrombotic Thrombocytopenic Purpura. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 436-442.	1.3	5
6	Solid Tumor Complicated With Venous Thromboembolism: A 10-Year Retrospective Cross-Sectional Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962097548.	0.7	9
7	Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?. <i>International Journal of Hematology</i> , 2021, 113, 330-336.	0.7	16
8	Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular coagulation treated with thrombomodulin alfa. <i>Thrombosis Journal</i> , 2021, 19, 12.	0.9	8
9	Evaluation of hemostatic abnormalities in patients who underwent major hepatobiliary pancreatic surgery using activated partial thromboplastin time-clot waveform analysis. <i>Thrombosis Research</i> , 2021, 201, 154-160.	0.8	7
10	Soluble C-Type Lectin-Like Receptor 2 Is a Biomarker for Disseminated Intravascular Coagulation. <i>Journal of Clinical Medicine</i> , 2021, 10, 2860.	1.0	16
11	Roles of Coagulation Abnormalities and Microthrombosis in Sepsis: Pathophysiology, Diagnosis, and Treatment. <i>Archives of Medical Research</i> , 2021, 52, 788-797.	1.5	32
12	Soluble C-Type Lectin-Like Receptor 2 Elevation in Patients with Acute Cerebral Infarction. <i>Journal of Clinical Medicine</i> , 2021, 10, 3408.	1.0	18
13	An evaluation of the Japanese Society on Thrombosis and Hemostasis criteria for disseminated intravascular coagulation as a predictor of prognosis in patients with infection. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1566-1574.	0.7	4
14	Coagulation factor V inhibitors, a review of the case report literature. <i>Thrombosis Update</i> , 2021, 4, 100058.	0.4	2
15	Evaluation of Biomarkers of Severity in Patients with COVID-19 Infection. <i>Journal of Clinical Medicine</i> , 2021, 10, 3775.	1.0	17
16	The Evaluation of APTT Reagents in Reference Plasma, Recombinant FVIII Products; Kovaltry® and Jivi® Using CWA, Including sTF/7FIX Assay. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962097691.	0.7	7
17	The Evaluation of Hemostatic Abnormalities Using a CWA-Small Amount Tissue Factor Induced FIX Activation Assay in Major Orthopedic Surgery Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110120.	0.7	7
18	The Reevaluation of Thrombin Time Using a Clot Waveform Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4840.	1.0	9

#	ARTICLE	IF	CITATIONS
19	A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms. <i>Journal of Clinical Medicine</i> , 2021, 10, 5352.	1.0	7
20	Clinical Features of Disseminated Intravascular Coagulation According to the French-American-British Classification in Patients With Acute Leukemia and Thrombomodulin Alfa Treatmentâ€”A Cohort Study Using a Postmarketing Surveillance Database. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110540.	0.7	5
21	Clot Waveform Analysis Demonstrates Low Blood Coagulation Ability in Patients with Idiopathic Thrombocytopenic Purpura. <i>Journal of Clinical Medicine</i> , 2021, 10, 5987.	1.0	4
22	Update on the Clot Waveform Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962091202.	0.7	27
23	Severe Antithrombin Deficiency May be Associated With a High Risk of Pathological Progression of DIC With Suppressed Fibrinolysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962094111.	0.7	4
24	The evaluation of a scoring system for diagnosing atypical hemolytic uremic syndrome. <i>Thrombosis Update</i> , 2020, 1, 100012.	0.4	2
25	Effects of platelet and phospholipids on clot formation activated by a small amount of tissue factor. <i>Thrombosis Research</i> , 2020, 193, 146-153.	0.8	13
26	The prothrombin time ratio is not a more effective marker for evaluating sepsisâ€”induced coagulopathy than fibrinâ€”related markers. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1506-1507.	1.9	5
27	Errors in the diagnosis for DIC due to a statistical misunderstanding. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1791-1792.	1.9	1
28	Analysis of the association between resolution of disseminated intravascular coagulation (DIC) and treatment outcomes in post-marketing surveillance of thrombomodulin alpha for DIC with infectious disease and with hematological malignancy by organ failure. <i>Thrombosis Journal</i> , 2020, 18, 2.	0.9	13
29	Elevated D-Dimer Levels Predict a Poor Outcome in Critically Ill Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962097308.	0.7	12
30	Major bleeding in a patient with warfarin-hypersensitive and factor IX propeptide variant, p.Ala37Thr, who was treated with a direct oral anti-Xa inhibitor. <i>Annals of Hematology</i> , 2019, 98, 209-210.	0.8	1
31	Usefulness of the APTT waveform for the diagnosis of DIC and prediction of the outcome or bleeding risk. <i>Thrombosis Journal</i> , 2019, 17, 12.	0.9	25
32	Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing antiâ€”idiotypic monoclonal antibodies: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 555-556.	1.9	4
33	Sepsis-associated disseminated intravascular coagulation and its differential diagnoses. <i>Journal of Intensive Care</i> , 2019, 7, 32.	1.3	42
34	The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases. <i>Thrombosis Research</i> , 2019, 179, 11-14.	0.8	41
35	Usefulness of Measuring Changes in SOFA Score for the Prediction of 28-Day Mortality in Patients With Sepsis-Associated Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961882404.	0.7	24
36	Comments to: An Evaluation of Hemostatic Abnormalities in Patients With Hemophilia by APTT Waveform, Peak Heights of APTT Waveform Are Useful for Diagnosing Hemophilia or Inhibitor. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961882441.	0.7	2

#	ARTICLE	IF	CITATIONS
37	Elevated plasma levels of soluble C-type lectin-like receptor 2 (CLEC2) in patients with thrombotic microangiopathy. <i>Thrombosis Research</i> , 2019, 178, 54-58.	0.8	19
38	Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 415-419.	1.9	50
39	An Evaluation of Hemostatic Abnormalities in Patients With Hemophilia According to the Activated Partial Thromboplastin Time Waveform. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1170-1176.	0.7	14
40	Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 1088-1099.	0.7	35
41	The Evaluation of Fibrin-Related Markers for Diagnosing or Predicting Acute or Subclinical Venous Thromboembolism in Patients Undergoing Major Orthopedic Surgery. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 107-114.	0.7	11
42	The Evaluation of D-Dimer Levels for the Comparison of Fibrinogen and Fibrin Units Using Different D-Dimer Kits to Diagnose VTE. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 655-662.	0.7	11
43	A Proposal of the Modification of Japanese Society on Thrombosis and Hemostasis (JSTH) Disseminated Intravascular Coagulation (DIC) Diagnostic Criteria for Sepsis-Associated DIC. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 439-445.	0.7	40
44	Platelet Activation Assessed by Glycoprotein VI/Platelet Ratio Is Associated With Portal Vein Thrombosis After Hepatectomy and Splenectomy in Patients With Liver Cirrhosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 254-262.	0.7	8
45	Monitoring of hemostatic abnormalities in major orthopedic surgery patients treated with edoxaban by APTT waveform. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 49-55.	0.7	16
46	An Evaluation of the Activated Partial Thromboplastin Time Waveform. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 764-770.	0.7	23
47	The Plasma Levels of ADAMTS-13, von Willebrand Factor, VWFpp, and Fibrin-Related Markers in Patients With Systemic Sclerosis Having Thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 920-927.	0.7	6
48	Prediction of Early Death in Patients With Sepsis-Associated Coagulation Disorder Treated With Antithrombin Supplementation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 145S-149S.	0.7	11
49	APTT waveform. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2018, 29, 413-420.	0.1	2
50	Clinical Manifestation of Patients With Atypical Hemolytic Uremic Syndrome With the C3p.I1157T Variation in the Kinki Region of Japan. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1301-1307.	0.7	12
51	Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. <i>Thrombosis Journal</i> , 2018, 16, 14.	0.9	75
52	Congenital Thrombophilia in Patients With Superior Mesenteric Venous Thrombosis or Portal Vein Thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1117-1121.	0.7	1
53	A re-evaluation of the D-dimer cutoff value for making a diagnosis according to the ISTH overt DIC diagnostic criteria: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1442-1444.	1.9	48
54	Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1665-1666.	1.9	26

#	ARTICLE	IF	CITATIONS
55	Hypofibrinogenemia and the β -Fibrinogen Thr312Ala Polymorphism may be Risk Factors for Early Pregnancy Loss. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 52-57.	0.7	10
56	Plasma ADAMTS13, von Willebrand Factor (VWF), and VWF Propeptide Profiles in Patients With Connective Tissue Diseases and Antiphospholipid Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 622-630.	0.7	10
57	Elevated Soluble Platelet Glycoprotein VI Levels in Patients After Living Donor Liver Transplantation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 274-281.	0.7	3
58	Protection From Pregnancy Loss in Women With Hereditary Thrombophilia When Associated With Fibrinogen Polymorphism Thr331Ala. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 494-495.	0.7	3
59	An Evaluation of the Modified Diagnostic Criteria for DIC Established by the Japanese Society of Thrombosis and Hemostasis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 579-584.	0.7	12
60	Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. <i>International Journal of Hematology</i> , 2017, 106, 3-15.	0.7	75
61	The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. <i>Thrombosis Journal</i> , 2017, 15, 17.	0.9	38
62	Comparison of three different anti-Xa assays in major orthopedic surgery patients treated with direct oral anticoagulant. <i>Thrombosis Journal</i> , 2017, 15, 27.	0.9	3
63	Evaluation of the Diagnostic Criteria for the Basic Type of DIC Established by the Japanese Society of Thrombosis and Hemostasis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 838-843.	0.7	12
64	High prevalence of congenital thrombophilia in patients with pregnancy-related or idiopathic venous thromboembolism/pulmonary embolism. <i>International Journal of Hematology</i> , 2017, 105, 272-279.	0.7	6
65	Platelets Activation and Liver Transplantation. <i>Journal of Liver</i> , 2017, 06, .	0.3	1
66	Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2308-2309.	1.9	3
67	Disease Recurrence After Early Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome With Complement C3 I1157T Mutation. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, e137-e139.	0.3	13
68	Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1314-1315.	1.9	2
69	Shock, acute disseminated intravascular coagulation, and microvascular thrombosis: is "shock liver" the unrecognized provocateur of ischemic limb necrosis: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2315-2316.	1.9	0
70	Presence of Antiphospholipid Antibodies as a Risk Factor for Thrombotic Events in Patients with Connective Tissue Diseases and Idiopathic Thrombocytopenic Purpura. <i>Internal Medicine</i> , 2016, 55, 589-595.	0.3	20
71	Comparison of three different anti-Xa assays in major orthopedic surgery patients treated with fondaparinux. <i>International Journal of Hematology</i> , 2016, 103, 554-559.	0.7	6
72	The valuable diagnosis of DIC and pre-DIC and prediction of a poor outcome by the evaluation of diagnostic criteria for DIC in patients with hematopoietic injury established by the Japanese Society of Thrombosis and Hemostasis. <i>Thrombosis Research</i> , 2016, 147, 80-84.	0.8	7

#	ARTICLE	IF	CITATIONS
73	Antithrombin supplementation and risk of bleeding in patients with sepsis-associated disseminated intravascular coagulation. <i>Thrombosis Research</i> , 2016, 145, 46-50.	0.8	16
74	Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. <i>Thrombosis Journal</i> , 2016, 14, 42.	0.9	130
75	Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity. <i>Critical Care</i> , 2016, 20, 287.	2.5	51
76	The efficacy of the administration of recombinant human soluble thrombomodulin in patients with DIC. <i>International Journal of Hematology</i> , 2016, 103, 173-179.	0.7	14
77	Fibrin-related markers for diagnosing acute-, subclinical-, and pre-venous thromboembolism in patients with major orthopedic surgery. <i>International Journal of Hematology</i> , 2016, 103, 560-566.	0.7	15
78	Antithrombin or thrombomodulin administration in severe pneumonia patients with sepsis and disseminated intravascular coagulation: comment on two papers. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 684-685.	1.9	3
79	Anti-Xa activity in VTE patients treated with fondaparinux. <i>Clinica Chimica Acta</i> , 2015, 442, 22-23.	0.5	6
80	Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 679-680.	1.9	2
81	High frequency of decreased antithrombin level in pregnant women with thrombosis. <i>International Journal of Hematology</i> , 2015, 102, 253-258.	0.7	8
82	Elevated soluble platelet glycoprotein VI is a useful marker for DVT in postoperative patients treated with edoxaban. <i>International Journal of Hematology</i> , 2014, 100, 450-456.	0.7	15
83	Natural History of Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 866-873.	1.5	33
84	Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation. <i>International Journal of Hematology</i> , 2014, 100, 437-442.	0.7	41
85	Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. <i>Critical Care</i> , 2014, 18, 497.	2.5	50
86	Addition of recommendations for the use of recombinant human thrombomodulin to the "Expert consensus for the treatment of disseminated intravascular coagulation in Japan". <i>Thrombosis Research</i> , 2014, 134, 924-925.	0.8	29
87	Is early treatment of disseminated intravascular coagulation beneficial in septic patients?. <i>Critical Care</i> , 2014, 18, 447.	2.5	7
88	Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. <i>Journal of Intensive Care</i> , 2014, 2, 15.	1.3	239
89	Clinical features and underlying causes of cerebral venous thrombosis in Japanese patients. <i>International Journal of Hematology</i> , 2014, 99, 437-440.	0.7	15
90	Elevated plasma levels of soluble platelet glycoprotein VI (GPVI) in patients with thrombotic microangiopathy. <i>Thrombosis Research</i> , 2014, 133, 440-444.	0.8	29

#	ARTICLE	IF	CITATIONS
91	Prolonged thrombocytopenia after living donor liver transplantation is a strong prognostic predictor irrespective of history of splenectomy: the significance of ADAMTS13 and graft function. <i>International Journal of Hematology</i> , 2014, 99, 418-428.	0.7	11
92	Disseminated intravascular coagulation: Testing and diagnosis. <i>Clinica Chimica Acta</i> , 2014, 436, 130-134.	0.5	69
93	Elevated Fibrin-related Markers in Patients with Malignant Diseases Frequently Associated with Disseminated Intravascular Coagulation and Venous Thromboembolism. <i>Internal Medicine</i> , 2014, 53, 413-419.	0.3	20
94	Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases. <i>International Journal of Hematology</i> , 2013, 97, 345-350.	0.7	11
95	Harmonized guidance for disseminated intravascular coagulation from the International Society on Thrombosis and Haemostasis and the current status of anticoagulant therapy in Japan: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 2078-2079.	1.9	22
96	Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 761-767.	1.9	366
97	The relationships among hemostatic markers, the withdrawal of fondaparinux due to a reduction in hemoglobin and deep vein thrombosis in Japanese patients undergoing major orthopedic surgery. <i>Clinica Chimica Acta</i> , 2013, 425, 109-113.	0.5	20
98	Behavior of ADAMTS13 and Von Willebrand factor levels in patients after living donor liver transplantation. <i>Thrombosis Research</i> , 2013, 131, 225-229.	0.8	19
99	Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. <i>Molecular Immunology</i> , 2013, 54, 238-246.	1.0	62
100	A Prospective Analysis of Disseminated Intravascular Coagulation in Patients with Infections. <i>Internal Medicine</i> , 2013, 52, 1893-1898.	0.3	17
101	Two Patients with Antiphospholipid Antibody Developed Disseminated Intravascular Coagulation. <i>Internal Medicine</i> , 2013, 52, 269-272.	0.3	3
102	Analysis of the Cutoff Values in Fibrin-Related Markers for the Diagnosis of Overt DIC. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 495-500.	0.7	12
103	Increased Ratio of Soluble Fibrin Formation/Thrombin Generation in Patients With DIC. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 628-632.	0.7	9
104	Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. <i>Expert Review of Hematology</i> , 2012, 5, 643-652.	1.0	33
105	Plasma ADAMTS13, von Willebrand Factor (VWF) and VWF Propeptide Profiles in Patients with DIC and Related Diseases. <i>Thrombosis Research</i> , 2012, 129, 598-602.	0.8	60
106	Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: A prospective multicenter survey. <i>Thrombosis Research</i> , 2012, 130, e129-e133.	0.8	63
107	Frequent association of thrombophilia in cerebral venous sinus thrombosis. <i>International Journal of Hematology</i> , 2012, 95, 257-262.	0.7	12
108	More on: racial differences in venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 319-320.	1.9	13

#	ARTICLE	IF	CITATIONS
109	Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux. <i>International Journal of Hematology</i> , 2012, 95, 160-166.	0.7	22
110	A novel protein S gene mutation combined with protein S Tokushima mutation in a patient with superior sagittal sinus thrombosis. <i>Journal of Neurology</i> , 2012, 259, 178-179.	1.8	5
111	Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases. <i>Thrombosis Research</i> , 2011, 128, 186-190.	0.8	48
112	Neutrophil elastase affects not only tissue damage, but it also regulates hematopoiesis. <i>Thrombosis Research</i> , 2011, 128, 205-206.	0.8	0
113	Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. <i>Thrombosis and Haemostasis</i> , 2011, 105, 40-44.	1.8	98
114	Diagnostic Criteria and Laboratory Tests for Disseminated Intravascular Coagulation. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2011, 51, 67-76.	0.3	56
115	Lethal hepatic infarction following plasma exchange in living donor liver transplant patients. <i>Transplant International</i> , 2011, 24, e57-e58.	0.8	4
116	Elevated Von Willebrand factor propeptide for the diagnosis of thrombotic microangiopathy and for predicting a poor outcome. <i>International Journal of Hematology</i> , 2011, 93, 47-52.	0.7	15
117	Monitoring for anti-Xa activity for prophylactic administration of Fondaparinux in patients with artificial joint replacement. <i>International Journal of Hematology</i> , 2011, 94, 355-360.	0.7	16
118	PCR Analysis of Bacteria and Fungi in Early Phase of Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 1963-1963.	0.6	0
119	Prevention of venous thromboembolism according to the guidelines of a domestic manual. <i>International Journal of Hematology</i> , 2010, 91, 909-911.	0.7	2
120	A second national questionnaire survey of TMA. <i>International Journal of Hematology</i> , 2010, 92, 68-75.	0.7	8
121	The association of protein S Tokushima-K196E with a risk of deep vein thrombosis. <i>International Journal of Hematology</i> , 2010, 92, 302-305.	0.7	35
122	Modified non-overlapped DIC diagnostic criteria predict the early phase of overt DIC. <i>American Journal of Hematology</i> , 2010, 85, 691-694.	2.0	35
123	Scores biologiques de CIVD. <i>Sang Thrombose Vaisseaux</i> , 2010, 22, 003-005.	0.1	1
124	Elevated Fibrin-Related Markers in Patients with Malignant Diseases Suspected of Having Thrombotic Disorders. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 266-272.	0.7	6
125	Expert consensus for the treatment of disseminated intravascular coagulation in Japan. <i>Thrombosis Research</i> , 2010, 125, 6-11.	0.8	222
126	Hemostatic abnormalities in the acute phase of trauma. <i>Thrombosis Research</i> , 2010, 126, 1-2.	0.8	41

#	ARTICLE	IF	CITATIONS
127	Evaluation of modified non-overt DIC criteria on the prediction of poor outcome in patients with sepsis. <i>Thrombosis Research</i> , 2010, 126, 18-23.	0.8	27
128	Analysis three abnormal Protein S genes in a patient with pulmonary embolism. <i>Thrombosis Research</i> , 2010, 125, 529-532.	0.8	9
129	Frequency and hemostatic abnormalities in pre-DIC patients. <i>Thrombosis Research</i> , 2010, 126, 74-78.	0.8	26
130	Diagnostic criteria for DIC based on the prospective study. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2010, 21, 600-605.	0.1	0
131	Clinical Practice in Hemophilia and Thrombophilia Center in Mie University. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2010, 21, 640-641.	0.1	0
132	Cut-off values of D-dimer and soluble fibrin for prediction of deep vein thrombosis after orthopaedic surgery. <i>International Journal of Hematology</i> , 2009, 89, 572-576.	0.7	43
133	National questionnaire survey of TMA. <i>International Journal of Hematology</i> , 2009, 90, 328-335.	0.7	5
134	Decreased ADAMTS13 Levels in Patients after Living Donor Liver Transplantation. <i>Thrombosis Research</i> , 2009, 124, 541-545.	0.8	31
135	Physiological Protease Inhibitor α^2 AT, APC. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2009, 20, 6-8.	0.1	0
136	Negative predictive value of d-dimer for diagnosis of venous thromboembolism. <i>International Journal of Hematology</i> , 2008, 87, 250-255.	0.7	51
137	Elevated levels of soluble fibrin in patients with venous thromboembolism. <i>International Journal of Hematology</i> , 2008, 88, 448-453.	0.7	19
138	ADAMTS13 related markers and von Willebrand factor in plasma from patients with thrombotic microangiopathy (TMA). <i>Thrombosis Research</i> , 2008, 121, 849-854.	0.8	16
139	Elevated Levels of Prothrombin Fragment 1 + 2 Indicate High Risk of Thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2008, 14, 279-285.	0.7	58
140	Hemostatic Abnormalities and Liver Diseases. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 772-778.	1.5	73
141	Are Fibrin-Related Markers Useful for the Diagnosis of Thrombosis?. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 033-038.	1.5	45
142	Pathophysiology and diagnostic criteria for disseminated intravascular coagulation associated with sepsis*. <i>Critical Care Medicine</i> , 2008, 36, 348-349.	0.4	3
143	Cutoff Values of D-Dimer and FDP in Plasma for the Diagnosis of Thrombosis. <i>Vascular Disease Prevention</i> , 2008, 5, 81-88.	0.2	0
144	Elevated Levels of Soluble Fibrin in Patients with Thrombosis or a Pre- Thrombotic State. <i>Vascular Disease Prevention</i> , 2008, 5, 227-233.	0.2	0

#	ARTICLE	IF	CITATIONS
145	Difference between sepsis and trauma diagnosed as sensitive diagnostic criteria for disseminated intravascular coagulation. <i>Thrombosis and Haemostasis</i> , 2008, 100, 958-959.	1.8	0
146	Decreased ADAMTS13 activity in plasma from patients with thrombotic thrombocytopenic purpura. <i>Thrombosis Research</i> , 2007, 119, 447-452.	0.8	19
147	PROTEINASE 3 EXPRESSION ON NEUTROPHIL MEMBRANES FROM PATIENTS WITH INFECTIOUS DISEASE. <i>Shock</i> , 2006, 26, 128-133.	1.0	18
148	Elevated levels of soluble fibrin or D-dimer indicate high risk of thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1253-1258.	1.9	95
149	Frequency of Abnormal Biphasic aPTT Clot Waveforms in Patients with Underlying Disorders Associated with Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2006, 12, 185-192.	0.7	48
150	Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 7036-7041.	3.3	100
151	Thrombomodulin accelerates activated protein C production and inhibits thrombin generation in the plasma of disseminated intravascular coagulation patients. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 17-24.	0.5	7
152	Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis. <i>American Journal of Hematology</i> , 2005, 78, 1-6.	2.0	9
153	Diagnosis of deep vein thrombosis by plasma-soluble fibrin or D-dimer. <i>American Journal of Hematology</i> , 2005, 79, 274-280.	2.0	47
154	Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. <i>Thrombosis and Haemostasis</i> , 2005, 94, 975-979.	1.8	208
155	Elevated Plasma Levels of Fibrin Degradation Products by Granulocyte-Derived Elastase in Patients with Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2005, 11, 391-400.	0.7	22
156	Evaluation of New Japanese Diagnostic Criteria for Disseminated Intravascular Coagulation in Critically Ill Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2005, 11, 71-76.	0.7	77
157	Annexin II overexpression correlates with a poor prognosis in surgically resected non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 7249-7249.	0.8	0
158	Hypercoagulant states in malignant lymphoma. <i>Experimental Oncology</i> , 2005, 27, 179-85.	0.4	22
159	Tissue factor messenger RNA levels in leukocytes compared with tissue factor antigens in plasma from patients in hypercoagulable state caused by various diseases. <i>Thrombosis and Haemostasis</i> , 2004, 92, 132-139.	1.8	22
160	Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit. <i>American Journal of Hematology</i> , 2004, 76, 225-229.	2.0	81
161	High prevalence of anti-prothrombin antibody in patients with deep vein thrombosis. <i>American Journal of Hematology</i> , 2004, 76, 338-342.	2.0	32
162	Disseminated intravascular coagulation. <i>Clinica Chimica Acta</i> , 2004, 344, 13-21.	0.5	93

#	ARTICLE	IF	CITATIONS
163	The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. <i>Seminars in Hematology</i> , 2004, 41, 68-74.	1.8	104
164	Increased Membrane Proteinase 3 Expression on Neutrophils in Patients with Infectious Disease.. <i>Blood</i> , 2004, 104, 3806-3806.	0.6	0
165	Initial Laboratory Findings Useful for Predicting the Diagnosis of Chronic ITP: Results of a Multicenter Prospective Study.. <i>Blood</i> , 2004, 104, 2061-2061.	0.6	0
166	High plasma fibrinogen level is associated with poor clinical outcome in DIC patients. <i>American Journal of Hematology</i> , 2003, 72, 1-7.	2.0	75
167	Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis (ISTH) and of the Japanese Ministry of Health and Welfare for overt DIC. <i>American Journal of Hematology</i> , 2003, 74, 17-22.	2.0	166
168	Increased Soluble Fibrin in Plasma of Patients with Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 233-240.	0.7	31
169	Effects of Lipid Abnormalities on Arteriosclerosis and Hemostatic Markers in Patients under Hemodialysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 203-210.	0.7	8
170	Measurement of tissue factor messenger RNA levels in leukocytes from patients in hypercoagulable state caused by several underlying diseases. <i>Thrombosis and Haemostasis</i> , 2003, 89, 660-665.	1.8	22
171	Measurement of tissue factor messenger RNA levels in leukocytes from patients in hypercoagulable state caused by several underlying diseases. <i>Thrombosis and Haemostasis</i> , 2003, 89, 660-5.	1.8	9
172	Molecular characterization of coagulation factor XII deficiency in a Japanese family. <i>Thrombosis and Haemostasis</i> , 2003, 90, 59-63.	1.8	2
173	Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. <i>Transfusion</i> , 2002, 42, 572-580.	0.8	121
174	Activity and Antigen Levels of Thrombin-Activatable Fibrinolysis Inhibitor in Plasma of Patients With Disseminated Intravascular Coagulation. <i>Thrombosis Research</i> , 2001, 104, 1-6.	0.8	88
175	Comparison of the Responses of Global Tests of Coagulation with Molecular Markers of Neutrophil, Endothelial, and Hemostatic System Perturbation in the Baboon Model of E. coli Sepsis. <i>Thrombosis and Haemostasis</i> , 2001, 86, 1489-1494.	1.8	24
176	Two-stage response to endotoxin infusion into normal human subjects: Correlation of blood phagocyte luminescence with clinical and laboratory markers of the inflammatory, hemostatic response. <i>Critical Care Medicine</i> , 2001, 29, 326-334.	0.4	44
177	Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation. <i>Thrombosis and Haemostasis</i> , 2001, 86, 1327-1330.	1.8	1,875
178	Increased Plasma Thrombomodulin as a Vascular Endothelial Cell Marker in Patients With Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2001, 7, 5-9.	0.7	26
179	Plasma Levels of Total Plasminogen Activator Inhibitor-I (PAI-I) and tPA/PAI-1 Complex in Patients With Disseminated Intravascular Coagulation and Thrombotic Thrombocytopenic Purpura. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2001, 7, 229-233.	0.7	37
180	Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. <i>Thrombosis and Haemostasis</i> , 2001, 86, 1327-30.	1.8	709

#	ARTICLE	IF	CITATIONS
181	Analyses of Serum Concentrations of Apolipoproteins in the Demented Elderly.. Internal Medicine, 2000, 39, 220-222.	0.3	4
182	Description of compensated and uncompensated disseminated intravascular coagulation (DIC) responses (non-overt and overt DIC) in baboon models of intravenous and intraperitoneal Escherichia coli sepsis and in the human model of endotoxemia: Toward a better definition of DIC. Critical Care Medicine, 2000, 28, S12-S19.	0.4	75
183	Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states. American Journal of Hematology, 2000, 65, 35-40.	2.0	28
184	Increased plasma levels of tissue factor pathway inhibitor-activated factor X complex in patients with disseminated intravascular coagulation. American Journal of Hematology, 2000, 65, 210-214.	2.0	8
185	State-of-the-Art Review : Coagulation Tests and Anti-Phospholipid Antibodies in Patients Positive for Lupus Anticoagulant. Clinical and Applied Thrombosis/Hemostasis, 2000, 6, 144-150.	0.7	7
186	Diagnosis of Disseminated Intravascular Coagulation by Hemostatic Molecular Markers. Seminars in Thrombosis and Hemostasis, 2000, Volume 26, 017-022.	1.5	24
187	State-of-the-Art Review : Outcome of Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome in Japan. Clinical and Applied Thrombosis/Hemostasis, 1999, 5, 110-112.	0.7	7
188	Hemostatic molecular markers before the onset of disseminated intravascular coagulation. , 1999, 60, 273-278.		55
189	Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease. , 1999, 61, 238-242.		26
190	Diffuse brain damage caused by acute twin-twin transfusion during late pregnancy. Pediatrics International, 1998, 40, 370-373.	0.2	9
191	The effects of glucose, mannose, fructose and lactate on the preservation of neural activity in the hippocampal slices from the guinea pig. Brain Research, 1998, 788, 144-150.	1.1	38
192	Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. , 1998, 58, 189-194.		58
193	Increased Plasma Soluble-adhesion Molecules in Thrombotic Thrombocytopenic Purpura and Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis, 1998, 4, 196-200.	0.7	4
194	Hemostatic Molecular Markers Before Onset of Disseminated Intravascular Coagulation in Leukemic Patients. Seminars in Thrombosis and Hemostasis, 1998, 24, 293-297.	1.5	31
195	Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation. Blood Coagulation and Fibrinolysis, 1998, 9, 491-498.	0.5	24
196	Blood-Brain Barrier Permeability of the Demented Elderly as Studied by Cerebrospinal Fluid-Serum Albumin Ratio.. Internal Medicine, 1998, 37, 509-513.	0.3	54
197	The effects of lactate and \hat{I}^2 -hydroxybutyrate on the energy metabolism and neural activity of hippocampal slices from adult and immature rat. Developmental Brain Research, 1997, 101, 1-7.	2.1	49
198	Effect of inorganic phosphate and ADP on the myofilament sliding induced by laser flash photolysis of caged ATP. Biochimica Et Biophysica Acta - Bioenergetics, 1996, 1274, 89-93.	0.5	2

#	ARTICLE	IF	CITATIONS
199	Plasma levels of activated FVII in various diseases. <i>Blood Coagulation and Fibrinolysis</i> , 1996, 7, 794-798.	0.5	10
200	Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. , 1996, 51, 255-260.		68
201	Tissue factor expression in endothelial cells in health and disease. <i>Blood Coagulation and Fibrinolysis</i> , 1995, 6, S26-S31.	0.5	42
202	Hemostatic abnormalities in patients with pulmonary embolism compared with that in deep vein thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 1995, 6, 627-633.	0.5	26
203	Decreased protein C inhibitor after percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction. <i>American Journal of Hematology</i> , 1995, 49, 1-5.	2.0	29
204	Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C. <i>American Journal of Hematology</i> , 1995, 50, 237-243.	2.0	30
205	Outcome of Disseminated Intravascular Coagulation in Relation to the Score when Treatment was Begun. <i>Thrombosis and Haemostasis</i> , 1995, 74, 848-852.	1.8	138
206	Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. <i>Mie DIC Study Group. Thrombosis and Haemostasis</i> , 1995, 74, 848-52.	1.8	61
207	Increased activated protein C-protein C inhibitor complex level in patients positive for lupus anticoagulant. <i>Blood Coagulation and Fibrinolysis</i> , 1994, 5, 173-178.	0.5	25
208	Increased activated protein C-protein C inhibitor complex levels in patients with pulmonary embolism. <i>Thrombosis and Haemostasis</i> , 1994, 71, 192-4.	1.8	37
209	Plasminogen activators and their inhibitors in leukemic cell homogenates. <i>American Journal of Hematology</i> , 1993, 42, 166-170.	2.0	28
210	Hemostatic study before onset of disseminated intravascular coagulation. <i>American Journal of Hematology</i> , 1993, 43, 190-194.	2.0	72
211	Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , 1993, 44, 101-105.	2.0	68
212	Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. <i>American Journal of Hematology</i> , 1993, 44, 112-116.	2.0	90
213	Successful treatment of deep vein thrombosis in homozygous protein C deficiency with activated protein C. <i>American Journal of Hematology</i> , 1993, 44, 218-219.	2.0	7
214	Spa Bathing Activates Fibrinolysis in Patients with Cerebral Infarction.. <i>Internal Medicine</i> , 1993, 32, 619-622.	0.3	4
215	Stimulation of tissue type plasminogen activator by leukaemic cell homogenates. <i>Blood Coagulation and Fibrinolysis</i> , 1993, 4, 591-598.	0.5	4
216	Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. <i>American Journal of Hematology</i> , 1992, 39, 20-24.	2.0	107

#	ARTICLE	IF	CITATIONS
217	Effect of Niceritrol on Coagulation and Fibrinolytic Systems in Patients with Hypercholesterolemia. The Journal of Japan Atherosclerosis Society, 1992, 20, 1005-1008.	0.0	0
218	Homozygous protein C deficiency: identification of a novel missense mutation that causes impaired secretion of the mutant protein C. Translational Research, 1992, 119, 682-9.	2.4	12
219	Plasma level of tumor necrosis factor in disseminated intravascular coagulation. American Journal of Hematology, 1991, 37, 147-151.	2.0	50
220	Dynamic fluctuations in blood of thrombin/antithrombin III complex (TAT). American Journal of Hematology, 1991, 38, 86-89.	2.0	36
221	Plasma Level of IL-1 β in Disseminated Intravascular Coagulation. Thrombosis and Haemostasis, 1991, 65, 364-368.	1.8	43
222	Effect of Pravastatin $\text{\textcircled{R}}$ on Coagulation and Fibrinolytic Systems in Patients with Hypercholesterolemia. Japanese Journal of Thrombosis and Hemostasis, 1991, 2, 501-504.	0.1	1
223	Platelet Function in Watanabe Heritable Hyperlipidemic Rabbits, a Model for the Progression of Atherosclerosis. Japanese Journal of Thrombosis and Hemostasis, 1991, 2, 29-33.	0.1	0
224	The Hypercoagulable State in Hypercholesterolemia. The Journal of Japan Atherosclerosis Society, 1991, 19, 829-832.	0.0	0
225	The Clinical Significance of Automatically Measured D-Dimer and its Relationship to Fibrin Degradation Products. Japanese Journal of Thrombosis and Hemostasis, 1991, 2, 511-517.	0.1	0
226	Plasma level of IL-1 beta in disseminated intravascular coagulation. Thrombosis and Haemostasis, 1991, 65, 364-8.	1.8	14
227	Disseminated mycobacterial infection in a hemophilia B patient with acquired immunodeficiency syndrome.. Japanese Journal of Medicine, 1990, 29, 442-447.	0.1	0
228	Hemodynamic and Morphological Changes in the Dog Kidney after Injection of 5% Ethanolamine Oleate into the Superior Vena cava. European Surgical Research, 1990, 22, 63-70.	0.6	17
229	Mammalian Histidine Decarboxylase and DOPA Decarboxylase. Annals of the New York Academy of Sciences, 1990, 585, 145-161.	1.8	3
230	Nerve Endings in Palm Skin Grafts. Annals of Plastic Surgery, 1989, 22, 461-466.	0.5	10
231	Hypercoagulable State in the Watanabe Heritable Hyperlipidemic Rabbit, an Animal Model for the Progression of Atherosclerosis. Thrombosis and Haemostasis, 1989, 61, 140-143.	1.8	27
232	Hypercoagulable state in the Watanabe heritable hyperlipidemic rabbit, an animal model for the progression of atherosclerosis. Effect of probucol on coagulation. Thrombosis and Haemostasis, 1989, 61, 140-3.	1.8	9
233	Anticoagulant Activity in Cell Homogenate of Adult T Cell Leukemia. Thrombosis and Haemostasis, 1988, 59, 197-201.	1.8	10
234	Effect of tissue-type plasminogen activator on platelet aggregation.. Blood & Vessel, 1988, 19, 636-639.	0.0	0

#	ARTICLE	IF	CITATIONS
235	Anticoagulant activity in cell homogenate of adult T cell leukemia. Thrombosis and Haemostasis, 1988, 59, 197-201.	1.8	3
236	EFFECT OF THE LIPOPROTEIN FRACTION FROM PLASMA-EUGLOBULIN ON THE PLASMINOGEN ACTIVATION. Thrombosis and Haemostasis, 1987, 58, 1578.	1.8	0
237	Coagulability in Watanabe heritable hyperlipidemic(WHHL) rabbit.. Blood & Vessel, 1987, 18, 482-485.	0.0	0
238	Modification of factor VIII by thrombin and factor Xa. Blood & Vessel, 1984, 15, 178-182.	0.0	0
239	Studies on platelet-activating factor (PAF) Effect of antiplatelet agents on the release of PAF from human platelets.. Blood & Vessel, 1984, 15, 507-509.	0.0	0
240	Coagulant and fibrinolytic activities in the leukemic cell lysates. Thrombosis Research, 1983, 30, 315-322.	0.8	51